{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:37:55Z","timestamp":1790793475078,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40273-021-01032-7","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T04:04:40Z","timestamp":1620273880000},"page":"789-807","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Economic Burden of Multiple Sclerosis in Low- and Middle\u2010Income Countries: A Systematic Review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2875-124X","authenticated-orcid":false,"given":"Jalal","family":"Dahham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-6502","authenticated-orcid":false,"given":"Rana","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-8207","authenticated-orcid":false,"given":"Ingrid","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-570X","authenticated-orcid":false,"given":"Silvia M. A. A.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-9258","authenticated-orcid":false,"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"1032_CR1","unstructured":"The Multiple Sclerosis International Federation, Atlas of MS, 3rd Edition (September 2020)."},{"key":"1032_CR2","unstructured":"Dua T, Rompani P, World Health Organization, Multiple Sclerosis International Federation, editors. Atlas: multiple sclerosis resources in the world, 2008. Geneva, Switzerland: World Health Organization; 2008."},{"key":"1032_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000444019","volume":"46","author":"S Eskandarieh","year":"2016","unstructured":"Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple sclerosis epidemiology in East Asia, South East Asia and South Asia: a systematic review. Neuroepidemiology. 2016;46:209\u201321.","journal-title":"Neuroepidemiology"},{"key":"1032_CR4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:16.","journal-title":"Lancet."},{"key":"1032_CR5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","volume":"48\u201349","author":"D Karussis","year":"2014","unstructured":"Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014;48\u201349:134\u201342.","journal-title":"J Autoimmun"},{"key":"1032_CR6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","volume":"15","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;15:938\u201352.","journal-title":"N Engl J Med."},{"key":"1032_CR7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bpa.2010.11.001","volume":"24","author":"E Zindler","year":"2010","unstructured":"Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol. 2010;24:551\u201362.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"1032_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02999222","volume":"14","author":"MAD Judicibus","year":"2007","unstructured":"Judicibus MAD, McCabe MP. The impact of the financial costs of multiple sclerosis on quality of life. Int J Behav Med. 2007;14:3\u201311.","journal-title":"Int J Behav Med."},{"key":"1032_CR9","unstructured":"Trisolini M, Honeycutt A, Wiener J, Lesesne S. RTI International 3040 Cornwallis Road Research Triangle Park, NC 27709 USA: 104."},{"key":"1032_CR10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jns.2007.01.065","volume":"256","author":"T Vollmer","year":"2007","unstructured":"Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci. 2007;256:S5-13.","journal-title":"J Neurol Sci"},{"key":"1032_CR11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u20131444.","journal-title":"Neurology"},{"key":"1032_CR12","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp.2006.090365","volume":"77","author":"G Kobelt","year":"2006","unstructured":"Kobelt G. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77:918\u201326.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1032_CR13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J. 2017;23:1123\u201336.","journal-title":"Mult Scler J"},{"key":"1032_CR14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2105\/AJPH.57.3.424","volume":"57","author":"DP Rice","year":"1967","unstructured":"Rice DP. Estimating the cost of illness. Am J Public Health Nations Health. 1967;57:424\u201340.","journal-title":"Am J Public Health Nations Health."},{"key":"1032_CR15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","volume":"29","author":"A Larg","year":"2011","unstructured":"Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653\u201371.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.healthpol.2005.07.016","volume":"77","author":"R Tarricone","year":"2006","unstructured":"Tarricone R. Cost-of-illness analysis. Health Policy. 2006;77:51\u201363.","journal-title":"Health Policy"},{"key":"1032_CR17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10198-010-0286-7","volume":"13","author":"B Svendsen","year":"2012","unstructured":"Svendsen B, Myhr K-M, Nyland H, Aarseth JH. The cost of multiple sclerosis in Norway. Eur J Health Econ. 2012;13:81\u201391.","journal-title":"Eur J Health Econ."},{"key":"1032_CR18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458512441566","volume":"18","author":"K Karampampa","year":"2012","unstructured":"Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18:7\u201315.","journal-title":"Mult Scler."},{"key":"1032_CR19","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1352458513488230","volume":"19","author":"AJ Palmer","year":"2013","unstructured":"Palmer AJ, Colman S, O\u2019Leary B, Taylor BV, Simmons RD. The economic impact of multiple sclerosis in Australia in 2010. Mult Scler. 2013;19:1640\u20136.","journal-title":"Mult Scler."},{"key":"1032_CR20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000331043","volume":"66","author":"JP Reese","year":"2011","unstructured":"Reese JP, John A, Wienemann G, Wellek A, Sommer N, Tackenberg B, et al. Economic burden in a German cohort of patients with multiple sclerosis. Eur Neurol. 2011;66:311\u201321.","journal-title":"Eur Neurol."},{"key":"1032_CR21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00019053-199915030-00003","volume":"15","author":"AN Grudzinski","year":"1999","unstructured":"Grudzinski AN, Hakim Z, Cox ER, Bootman JL. The economics of multiple sclerosis: distribution of costs and relationship to disease severity. Pharmacoeconomics. 1999;15:229\u201340.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR22","doi-asserted-by":"crossref","first-page":"s54","DOI":"10.1007\/s10198-005-0289-y","volume":"5","author":"G Kobelt","year":"2004","unstructured":"Kobelt G. Economic evidence in multiple sclerosis: a review. Eur J Health Econ. 2004;5:s54-62.","journal-title":"Eur J Health Econ."},{"key":"1032_CR23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1191\/1352458505ms1137oa","volume":"11","author":"MB Patwardhan","year":"2005","unstructured":"Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11:232\u20139.","journal-title":"Mult Scler."},{"key":"1032_CR24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/14737167.6.2.145","volume":"6","author":"E Orlewska","year":"2006","unstructured":"Orlewska E. Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies? Expert Rev Pharmacoecon Outcomes Res. 2006;6:145\u201354.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1032_CR25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3111\/13696998.2013.778268","volume":"16","author":"G Adelman","year":"2013","unstructured":"Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16:639\u201347.","journal-title":"J Med Econ"},{"key":"1032_CR26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1590\/0004-282X20130082","volume":"71","author":"M Romano","year":"2013","unstructured":"Romano M, Machnicki G, Rojas JI, Frider N, Correale J. There is much to be learnt about the costs of multiple sclerosis in Latin America. Arq Neuro-Psiquiatr. 2013;71:549\u201355.","journal-title":"Arq Neuro-Psiquiatr."},{"key":"1032_CR27","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2165\/11538000-000000000-00000","volume":"70","author":"J Sharac","year":"2010","unstructured":"Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010;70:1677\u201391.","journal-title":"Drugs"},{"key":"1032_CR28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/00023210-200418090-00002","volume":"18","author":"CJ Phillips","year":"2004","unstructured":"Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs. 2004;18:561\u201374.","journal-title":"CNS Drugs"},{"key":"1032_CR29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3111\/13696998.2010.525989","volume":"13","author":"A Wundes","year":"2010","unstructured":"Wundes A, Brown T, Bienen EJ, Coleman CI. Contribution of intangible costs to the economic burden of multiple sclerosis. J Med Econ. 2010;13:626\u201332.","journal-title":"J Med Econ"},{"key":"1032_CR30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40273-016-0468-y","volume":"35","author":"J Oliva-Moreno","year":"2017","unstructured":"Oliva-Moreno J, Trapero-Bertran M, Pe\u00f1a-Longobardo LM, del Pozo-Rubio R. The valuation of informal care in cost-of-illness studies: a systematic review. Pharmacoeconomics. 2017;35:331\u201345.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR31","doi-asserted-by":"crossref","first-page":"e0159129","DOI":"10.1371\/journal.pone.0159129","volume":"11","author":"O Ernstsson","year":"2016","unstructured":"Ernstsson O, Gyllensten H, Alexanderson K, Tingh\u00f6g P, Friberg E, Norlund A. Cost of illness of multiple sclerosis\u2014a systematic review. PLoS One. 2016;11:e0159129.","journal-title":"PLoS One"},{"key":"1032_CR32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3111\/13696998.2013.807267","volume":"16","author":"K Karampampa","year":"2013","unstructured":"Karampampa K, Gustavsson A, van Munster EThL, Hupperts RMM, Sanders EACM, Mostert J, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ. 2013;16:939\u201350.","journal-title":"J Med Econ"},{"issue":"1","key":"1032_CR33","first-page":"75","volume":"67","author":"K Kolasa","year":"2013","unstructured":"Kolasa K. How much is the cost of multiple sclerosis\u2013systematic literature review. Przegl Epidemiol. 2013;67(1):75.","journal-title":"Przegl Epidemiol"},{"key":"1032_CR34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11532230-000000000-00000","volume":"28","author":"H Naci","year":"2010","unstructured":"Naci H, Fleurence R, Birt J, Duhig A. Economic Burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics. 2010;28:363\u201379.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR35","doi-asserted-by":"crossref","first-page":"102162","DOI":"10.1016\/j.msard.2020.102162","volume":"43","author":"M Paz-Zulueta","year":"2020","unstructured":"Paz-Zulueta M, Par\u00e1s-Bravo P, Cantarero-Prieto D, Bl\u00e1zquez-Fern\u00e1ndez C, Oterino-Dur\u00e1n A. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020;43:102162.","journal-title":"Mult Scler Relat Disord"},{"key":"1032_CR36","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1177\/1352458511405562","volume":"17","author":"J Risco","year":"2011","unstructured":"Risco J, Maldonado H, Luna L, Osada J, Ruiz P, Juarez A, et al. Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler. 2011;17:1055\u20139.","journal-title":"Mult Scler."},{"key":"1032_CR37","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jval.2011.05.023","volume":"14","author":"M Romero","year":"2011","unstructured":"Romero M, Arango C, Alvis N, Suarez JC, Duque A. Costos de la Esclerosis M\u00faltiple en Colombia. Value in Health. 2011;14:S48-50.","journal-title":"Value in Health."},{"issue":"7","key":"1032_CR38","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med."},{"key":"1032_CR39","unstructured":"World Bank Country and Lending Groups. 2020. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups. Accessed Apr 2020."},{"key":"1032_CR40","unstructured":"PPP conversion factor, GDP (LCU per international $). 2020. https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP. Accessed Apr 2020."},{"key":"1032_CR41","unstructured":"Inflation Calculator. 2020. https:\/\/cpiinflationcalculator.com\/ Accessed Apr 2020."},{"key":"1032_CR42","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00019053-199813050-00012","volume":"13","author":"F Henriksson","year":"1998","unstructured":"Henriksson F, J\u00f6nsson B. The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics. 1998;13:597\u2013606.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1590\/0004-282X20140016","volume":"72","author":"C Ysrraelit","year":"2014","unstructured":"Ysrraelit C, Caceres F, Villa A, Marcilla MP, Blanche J, Burgos M, et al. ENCOMS: Argentinian survey in cost of illness and unmet needs in multiple sclerosis. Arq Neuro Psiquiatr. 2014;72:337\u201343.","journal-title":"Arq Neuro Psiquiatr"},{"key":"1032_CR44","doi-asserted-by":"crossref","first-page":"e0208837","DOI":"10.1371\/journal.pone.0208837","volume":"14","author":"G Kobelt","year":"2019","unstructured":"Kobelt G, Teich V, Cavalcanti M, Canzonieri AM. Burden and cost of multiple sclerosis in Brazil. PLoS One. 2019;14:e0208837.","journal-title":"PLoS One"},{"key":"1032_CR45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3111\/13696998.2014.950420","volume":"18","author":"R Karabudak","year":"2015","unstructured":"Karabudak R, Karampampa K, \u00c7al\u0131\u015fkan Z, on behalf of the TRIBUNE Study Group. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey. J Med Econ. 2015;18:69\u201375.","journal-title":"J Med Econ"},{"key":"1032_CR46","first-page":"8","volume":"5","author":"A Torabipour","year":"2014","unstructured":"Torabipour A, Asl ZA, Majdinasab N, Ghasemzadeh R, Tabesh H, Arab M. A study on the direct and indirect costs of multiple sclerosis based on expanded disability status scale score in Khuzestan, Iran. Int J Prev Med. 2014;5:8.","journal-title":"Int J Prev Med"},{"key":"1032_CR47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1352458517708668","volume":"23","author":"A Boyko","year":"2017","unstructured":"Boyko A, Kobelt G, Berg J, Boyko O, Popova E, Capsa D, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia. Mult Scler. 2017;23:155\u201365.","journal-title":"Mult Scler."},{"key":"1032_CR48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12913-016-1352-3","volume":"16","author":"NL da Silva","year":"2016","unstructured":"da Silva NL, Takemoto MLS, Damasceno A, Fragoso YD, Finkelsztejn A, Becker J, et al. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study. BMC Health Serv Res. 2016;16:102.","journal-title":"BMC Health Serv Res."},{"key":"1032_CR49","doi-asserted-by":"crossref","first-page":"e0199446","DOI":"10.1371\/journal.pone.0199446","volume":"13","author":"DI Maia","year":"2018","unstructured":"Maia DI, Guerra AA, de Lemos LLP, Souza KM, Godman B, Bennie M, et al. The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. PLoS One. 2018;13:e0199446.","journal-title":"PLoS One"},{"key":"1032_CR50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vhri.2017.12.001","volume":"17","author":"IM Mu\u00f1oz-Galindo","year":"2018","unstructured":"Mu\u00f1oz-Galindo IM, Moreno Calder\u00f3n JA, Guar\u00edn T\u00e9llez NE, Ar\u00e9valo Roa HO, D\u00edaz Rojas JA. Health care cost for multiple sclerosis: the case of a Health Insurer in Colombia. Value Health Reg Issues. 2018;17:14\u201320.","journal-title":"Value Health Reg Issues."},{"key":"1032_CR51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13031-015-0038-5","volume":"9","author":"ED McKenzie","year":"2015","unstructured":"McKenzie ED, Spiegel P, Khalifa A, Mateen FJ. Neuropsychiatric disorders among Syrian and Iraqi refugees in Jordan: a retrospective cohort study 2012\u20132013. Confl Health. 2015;9:10.","journal-title":"Confl Health."},{"key":"1032_CR52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13023-019-1165-7","volume":"14","author":"R Min","year":"2019","unstructured":"Min R, Zhang X, Fang P, Wang B, Wang H. Health service security of patients with 8 certain rare diseases: evidence from China\u2019s national system for health service utilization of patients with healthcare insurance. Orphanet J Rare Dis. 2019;14:204.","journal-title":"Orphanet J Rare Dis."},{"key":"1032_CR53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s13760-013-0200-z","volume":"113","author":"MA Mac\u00edas-Islas","year":"2013","unstructured":"Mac\u00edas-Islas MA, Soria-Cedillo IF, Velazquez-Quintana M, Rivera VM, Baca-Muro VI, Lemus-Carmona EA, et al. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg. 2013;113:415\u201320.","journal-title":"Acta Neurol Belg."},{"key":"1032_CR54","doi-asserted-by":"crossref","first-page":"260","DOI":"10.29090\/psa.2019.04.018.0027","volume":"46","author":"C Chanatittarat","year":"2019","unstructured":"Chanatittarat C, Chaikledkaew U, Prayoonwiwat N, Siritho S, Pasogpakdee P, Apiwattanakul M, et al. Economic burden of Thai patients with inflammatory demyelinating central nervous system disorders (IDCD. Pharm Sci Asia. 2019;46:260\u20139.","journal-title":"Pharm Sci Asia."},{"key":"1032_CR55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12883-020-01790-5","volume":"20","author":"A Imani","year":"2020","unstructured":"Imani A, Gharibi F, Khezri A, Joudyian N, Dalal K. Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran. BMC Neurol. 2020;20:205.","journal-title":"BMC Neurol."},{"key":"1032_CR56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14737167.2020.1722103","volume":"21","author":"Y Du","year":"2020","unstructured":"Du Y, Min R, Zhang X, Fang P. Factors associated with the healthcare expenditures of patients with multiple sclerosis in urban areas of China estimated by a generalized estimating equation. Expert Rev Pharmacoecon Outcomes Res. 2020;21:137\u201344.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"1032_CR57","doi-asserted-by":"crossref","unstructured":"Schneider F, Buehn A, Montenegro CE. Shadow economies all over the world: New estimates for 162 countries from 1999 to 2007. World Bank policy research working paper. 2010 (5356).","DOI":"10.1596\/1813-9450-5356"},{"key":"1032_CR58","doi-asserted-by":"crossref","unstructured":"Schneider F, Klinglmair R. Shadow economies around the world: What do we know? 2004. https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=518526. Accessed 15 July 2020.","DOI":"10.2139\/ssrn.518526"},{"key":"1032_CR59","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2307\/3349801","volume":"60","author":"TA Hodgson","year":"1982","unstructured":"Hodgson TA, Meiners MR. Cost-of-Illness methodology: a guide to current practices and procedures. Milbank Meml Fund Q Health Soc. 1982;60:429.","journal-title":"Milbank Meml Fund Q Health Soc"},{"key":"1032_CR60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1524-4733.2007.00210.x","volume":"11","author":"G Clabaugh","year":"2008","unstructured":"Clabaugh G, Ward MM. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health. 2008;11:13\u201321.","journal-title":"Value Health."},{"key":"1032_CR61","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2165\/00019053-200624090-00005","volume":"24","author":"E Akobundu","year":"2006","unstructured":"Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmacoeconomics. 2006;24:869\u201390.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12961-018-0280-6","volume":"16","author":"A Luz","year":"2018","unstructured":"Luz A, Santatiwongchai B, Pattanaphesaj J, Teerawattananon Y. Identifying priority technical and context-specific issues in improving the conduct, reporting and use of health economic evaluation in low- and middle-income countries. Health Res Policy Syst. 2018;16:4.","journal-title":"Health Res Policy Syst."},{"key":"1032_CR63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40273-015-0325-4","volume":"34","author":"E Onukwugha","year":"2016","unstructured":"Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics. 2016;34:43\u201358.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR64","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1017\/S0266462312000530","volume":"28","author":"M Franken","year":"2012","unstructured":"Franken M, le Polain M, Cleemput I, Koopmanschap M. Similarities and differences between five European drug reimbursement systems. Int J Technol Assess Health Care. 2012;28:349\u201357.","journal-title":"Int J Technol Assess Health Care."},{"key":"1032_CR65","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2165\/00019053-200422130-00004","volume":"22","author":"R Welte","year":"2004","unstructured":"Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004;22:857\u201376.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR66","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40273-013-0053-6","volume":"31","author":"F-L Zhao","year":"2013","unstructured":"Zhao F-L, Xie F, Hu H, Li S-C. Transferability of indirect cost of chronic disease: a systematic review and meta-analysis. Pharmacoeconomics. 2013;31:501\u20138.","journal-title":"Pharmacoeconomics"},{"key":"1032_CR67","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1524-4733.2008.00491.x","volume":"12","author":"SD Sullivan","year":"2009","unstructured":"Sullivan SD. The transferability of economic data: a difficult endeavor. Value Health. 2009;12:408.","journal-title":"Value Health"},{"key":"1032_CR68","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1524-4733.2010.00699.x","volume":"13","author":"S Knies","year":"2010","unstructured":"Knies S, Severens JL, Ament AJHA, Evers SMAA. The transferability of valuing lost productivity across jurisdictions. Differences between National Pharmacoeconomic Guidelines. Value Health. 2010;13:519\u201327.","journal-title":"Value Health."},{"key":"1032_CR69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10198-019-01066-x","volume":"20","author":"V Brodszky","year":"2019","unstructured":"Brodszky V, Beretzky Z, Baji P, Rencz F, P\u00e9ntek M, Rotar A, et al. Cost-of-illness studies in nine Central and Eastern European countries. Eur J Health Econ. 2019;20:155\u201372.","journal-title":"Eur J Health Econ."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01032-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T12:54:03Z","timestamp":1672059243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01032-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01032-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"19 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jalal Dahham, Rana Rizk, Ingrid Kremer, Silvia M.A.A. Evers, and Micka\u00ebl Hiligsmann have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the data supporting the findings of this study (i.e., search strategy and the information extracted from the studies included in the review) are available within the article and the electronic supplementary material.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the concept and design. JD performed the searches. JD and RR conducted the title and abstract screening. JD, RR, and IK conducted the full-text screening, data extraction, and quality assessment. JD drafted the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}